EpiCept Corporation recently announced operating and financial results for the year 2010, and provided an update on its key business initiatives.
EpiCept’s lead product, Ceplene, is approved for marketing in the EU for the maintenance of first remission in patients with acute myeloid leukemia.
Jack Talley, President and CEO of the EpiCept Corporation, discusses his company with William Dawson of LifeTech Capital at the 2010 OneMedForum in San Francisco.
Copyright © 2025 | WordPress Theme by MH Themes